Enhanced surveillance of primary measles mumps and rubella (MMR) immunisation in Wales.
In England and Wales routinely available data measure uptake of the measles mumps and rubella (MMR) vaccine at 2 years. This results in a delay in detecting change in uptake of the vaccine, which is scheduled at 12 months of age. The predictive value of uptake at 15-17 months is limited by the greater variability in uptake between quarters at the younger age. This can be overcome by presenting the data as a four-quarter annual rolling average. Uptake of the MMR vaccine at 2 years of age in Wales is predicted to stabilise at around 84% in the first three quarters of 2002.
Mason
Brendan W
BW
Public Health Laboratory Service, Communicable Disease Surveillance Centre (Wales), Abton House, Wedal Road, CF14 3QX, Cardiff, UK. brendan.mason@phls.wales.nhs.uk
Thomas
Daniel R h
DR
Salmon
Roland L
RL
D002675:Child, Preschool; D006801:Humans; D017589:Immunization Programs / Q000379:methods* / Q000706:statistics & numerical data* / Q000600:supply & distribution; D007115:Immunization Schedule; D007223:Infant; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage*; D011159:Population Surveillance / Q000379:methods*; D011237:Predictive Value of Tests; D011446:Prospective Studies
D022542:Measles-Mumps-Rubella Vaccine